Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Companies / MC2 Therapeutics
Entity

MC2 Therapeutics

Tracked across 1 events · 6 articles · First seen Aug 20, 2026 · Last active Aug 20, 2026

Sentiment
20
Attention
2
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
2 20
Business
Knight Therapeutics launches WYNZORA in Canada
Knight Therapeutics Inc. announced the launch of WYNZORA, a topical cream for psoriasis vulgaris, in Canada. WYNZORA is a fixed-dose combination of calcipotriol and betamethasone dipropionate, developed by MC2 Therapeutics using its PAD Technology platform.…
Impact: MC2 Therapeutics is the developer and licensor of WYNZORA; the Canadian launch expands its product's global reach and validates its PAD Technology platform.
Aug 20, 2026 · 6 articles
Key Actions (1)
60 Paladin Pharma Inc. entered license agreement MC2 TherapeuticsKnight Therapeutics...
ERGEN INTELLIGENCE
Track MC2 Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.